Letrozole in Treating Breast Cancer in Postmenopausal Women With Stage I, II, or III Breast Cancer Previously Treated With Tamoxifen (GIM4)

Breast Cancer Clinical Trial

— GIM4  

Official title:

Letrozole Adjuvant Therapy Duration (LEAD) Study: Standard Versus Long Treatment. A Phase III Trial in Post-Menopausal Women With Early Breast Cancer.

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01064635
• Other study ID #: CDR0000665188
• Secondary ID: GIM-4-LEAD2005-0
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: August 2005
• Est. completion date: August 2026

Study information

• Verified date: May 2024
• Source: IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Estrogen can cause the growth of breast cancer cells. Letrozole may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known which regimen of letrozole is most effective in treating breast cancer in postmenopausal women who have received tamoxifen. PURPOSE: This randomized phase III trial is comparing different regimens of letrozole to see how well they work in treating postmenopausal women with stage I, stage II, or stage III breast cancer previously treated with tamoxifen.

Description:

OBJECTIVES: Primary - To compare the disease-free survival of previously treated, post-menopausal women with early-stage breast cancer treated with standard- (2-3 years of tamoxifen followed by 2-3 years of letrozole) versus long-treatment (2-3 years of tamoxifen followed by 5 years of letrozole) adjuvant letrozole. Secondary - To compare the overall survival of these patients. - To compare the safety of these patients. OUTLINE: Patients are randomized to 1 or 2 treatment arms. - Arm I (standard treatment): Patients previously treated with tamoxifen for 2 years receive letrozole for an additional 3 years; patients previously treated with tamoxifen for 3 years receive letrozole for an additional 2 years; and patients previously treated with tamoxifen for 2-3 years receive letrozole , so the total duration of the endocrine treatment (i.e., tamoxifen followed by letrozole) is 5 years. - Arm II (long treatment): Patients receive letrozole for an additional 5 years regardless of the duration of the previous tamoxifen treatment.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 2056
• Est. completion date: August 2026
• Est. primary completion date: August 2015
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

INCLUSION CRITERIA

• Signed informed consent prior to beginning protocol specific procedures.
• Histologically proven breast cancer at the first diagnosis with tumor stage I-II-III. Patients with histologically documented (microscopic) infiltration of the skin (pT4) will also be eligible.
• Axillary Nodal status allowed: Nx, pNo, pN1, pN2, pN3.
• Postmenopausal status defined by one of the following:
• Age > 55 years with cessation of menses
• Age < 55 years but not spontaneous menses for at least 1 year
• Age < 55 years and spontaneous menses within the past 1 year, but currently amenorrheic (e.g. spontaneous, or secondary to hysterectomy), AND with postmenopausal gonadotrophin levels (luteinizing hormone and follicle stimulating hormone levels >40 IU/L) or postmenopausal estradiol levels (<5 ng/dL) or according to the definition of "postmenopausal range" for the laboratory involved.
• Bilateral oophorectomy
• Adjuvant TAM received for at least 2 years and not more than 3 years and 3 months. Patients treated with adjuvant chemotherapy, are required to have begun receiving TAM within 3 months after the completion of chemotherapy.
• Definitive surgical treatment must be either mastectomy or breast conserving surgery, with axillary lymph node dissection or sentinel node biopsy for operable breast cancer.
• ECOG/WHO performance Status 0-1. Patients must be accessible for treatment and follow-up.
• Concomitant treatment with biphosphonates are allowed and should be recorded during the trial. EXCLUSION CRITERIA
• Male patients.
• Any locally advanced (T4) or inflammatory breast cancer. However, patients with microscopic infiltration of the skin (pT4) will be eligible.
• Patients with distant metastases. Any suspicious manifestation requires appropriate investigation to exclude metastases.
• Histology other than adenocarcinoma.
• Patients with previous or concomitant (not breast cancer) malignancy within the past 5 years EXCEPT adequately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix. Patients who have had a previous other malignancy must have been disease free for 5 years.
• Patients with other non-malignant systemic diseases (cardiovascular, renal, hepatic, lung embolism, etc.) which would prevent prolonged follow-up.
• Use of hormone Replacement Therapy within four weeks before randomization.
• Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational regimen within 30 days prior to study entry.
• Concurrent treatment with any other anti-cancer therapy.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Letrozole
letrozole for 2-3 years after Tam
• Letrozole
Letrozole for 5 years after Tam

Locations

Country	Name	City	State
Italy	Istituto Nazionale per la Ricerca sul Cancro	Genoa

Sponsors (1)

Lead Sponsor	Collaborator
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease-free survival		6 years after the last patient enters the study
Secondary	Overall survival		6 years after the last patient enters the study
Secondary	Safety		6 years after the last patient enters the study

External Links

•   Clinical trial summary from the National Cancer Institute's PDQ® database